| Biogenerics | Biogenerics (also called follow-on biologics) are generic (non-brand-name, nonproprietary) versions of biotechnology drugs. The United States Food and Drug Administration is trying to establish a set of procedures for the approval of biogenerics, because experts agree that it is much more difficult to exactly copy a biotechnology drug than traditional drugs. If a safe and fair official pathway for biogenerics can be developed, these drugs will be much less expensive than the originals that they are copying. But there is much debate about exactly how much money biogenerics will save the health care system. (See Food and Drug Administration [FDA].)
|
